{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:21:00Z","timestamp":1788351660846,"version":"build-2803163510"},"reference-count":73,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of off-label low-dose versus standard-dose antiplatelet agents in coronary heart disease (CHD) patients, focusing on the evidence gap in comparisons of low-dose versus standard-dose ticagrelor and prasugrel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure and Wanfang databases were searched up to 11 May 2025 for randomised controlled trials. Study quality was assessed using the Cochrane Risk of Bias 2.0 tool. A meta-analysis was performed, with relative risk (RR) and 95% CI as the effect estimates. Subgroup analyses were performed stratified by antiplatelet agent type, ethnic region, treatment duration and CHD subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 22 randomised controlled trials, involving 7486 patients, met the study criteria. Among them, 92.09% were Asian, and 63.63% of the included studies exclusively enrolled acute coronary syndrome patients. All patients received the dual antiplatelet therapy (aspirin combined with a low or standard dose of P2Y12 receptor antagonist), mainly with low-dose prasugrel and ticagrelor. Off-label low-dose antiplatelet agents significantly reduced myocardial infarction (MI) (RR 0.75, 95%\u2009CI 0.58 to 0.97) and minimal bleeding risks (RR 0.64, 95%\u2009CI 0.50 to 0.82) compared with standard doses, with comparable risks for other ischaemic and bleeding events. Compared with standard-dose clopidogrel, they significantly reduced MI risk (RR 0.71, 95%\u2009CI 0.54 to 0.93) but increased overall (RR 1.40, 95%\u2009CI 1.11 to 1.77) and minor bleeding risks (RR 1.86, 95%\u2009CI 1.02 to 3.38). Compared with standard-dose prasugrel or ticagrelor, they demonstrated comparable ischaemic risks and significantly reduced overall and minimal bleeding risks. All other subgroup analyses were consistent with the overall findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Off-label low-dose antiplatelet therapy reduces the risks of MI and minimal bleeding. It surpassed standard-dose clopidogrel and offered lower bleeding risks than prasugrel or ticagrelor, thus representing an effective secondary prevention strategy for Asian CHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023438376.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003839","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:30:23Z","timestamp":1769772623000},"page":"e003839","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of off-label low-dose compared with standard-dose antiplatelet agents in patients with coronary heart disease: a meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"given":"Li","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Genertec Aerospace Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-7762","authenticated-orcid":false,"given":"Zhao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Peking University Aerospace School of Clinical Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Peking University Aerospace School of Clinical Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Peking University Aerospace School of Clinical Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking University Aerospace School of Clinical Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichaoyue","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026090204550774000_13.1.e003839.1","doi-asserted-by":"crossref","unstructured":"Tsuboi H , Kondo K , Kaneko H , et al . Coronary heart disease. In: Social determinants of health in non-communicable diseases. 2020: 41\u201352.","DOI":"10.1007\/978-981-15-1831-7_5"},{"key":"2026090204550774000_13.1.e003839.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01917-8"},{"key":"2026090204550774000_13.1.e003839.3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023","volume":"86","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026090204550774000_13.1.e003839.4","first-page":"55","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"13","author":"Byrne","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026090204550774000_13.1.e003839.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001309"},{"key":"2026090204550774000_13.1.e003839.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae177"},{"key":"2026090204550774000_13.1.e003839.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.029"},{"key":"2026090204550774000_13.1.e003839.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1800722"},{"key":"2026090204550774000_13.1.e003839.9","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091201.39590.CB"},{"key":"2026090204550774000_13.1.e003839.10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/09537104.2020.1732328","article-title":"Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)","volume":"32","author":"Shi","year":"2021","journal-title":"Platelets"},{"key":"2026090204550774000_13.1.e003839.11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00380-012-0318-6","article-title":"Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial","volume":"29","author":"Ohkubo","year":"2014","journal-title":"Heart Vessels"},{"key":"2026090204550774000_13.1.e003839.12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122699","article-title":"Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial","volume":"10","author":"Jin","year":"2021","journal-title":"J Clin Med"},{"key":"2026090204550774000_13.1.e003839.13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.amjcard.2017.04.010","article-title":"Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention","volume":"120","author":"Choi","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026090204550774000_13.1.e003839.14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/clc.23517","article-title":"Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction","volume":"44","author":"Wang","year":"2021","journal-title":"Clin Cardiol"},{"key":"2026090204550774000_13.1.e003839.15","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-1482"},{"key":"2026090204550774000_13.1.e003839.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002303"},{"key":"2026090204550774000_13.1.e003839.17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7326\/M20-1806","article-title":"Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes\u202f: Results From a Randomized Trial","volume":"173","author":"Menichelli","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026090204550774000_13.1.e003839.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2004","article-title":"Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment","volume":"3","author":"Shoji","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026090204550774000_13.1.e003839.19","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1536\/ihj.20-772","article-title":"Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI","volume":"62","author":"Hu","year":"2021","journal-title":"Int Heart J"},{"key":"2026090204550774000_13.1.e003839.20","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2019-137180"},{"key":"2026090204550774000_13.1.e003839.21","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10557-021-07202-1","article-title":"Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis","volume":"36","author":"Wongsalap","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026090204550774000_13.1.e003839.22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4103\/0019-5049.171555","article-title":"Off-label use of drugs: An evil or a necessity?","volume":"59","author":"Gota","year":"2015","journal-title":"Indian J Anaesth"},{"key":"2026090204550774000_13.1.e003839.23","unstructured":"European Patients\u2019 Academy (EUPATI) . Off-label use of medicines. 2025. Available: https:\/\/toolbox.eupati.eu\/resources\/off-label-use\/(accessed [Accessed 16 Dec 2025]."},{"key":"2026090204550774000_13.1.e003839.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026090204550774000_13.1.e003839.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"2026090204550774000_13.1.e003839.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"2026090204550774000_13.1.e003839.27","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/clc.23075","article-title":"Efficacy and safety of short\u2010term dual antiplatelet therapy (\u22646 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta\u2010analysis of randomized controlled trials","volume":"41","author":"Misumida","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026090204550774000_13.1.e003839.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-022-02900-6","article-title":"Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials","volume":"22","author":"Parfrey","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"2026090204550774000_13.1.e003839.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026090204550774000_13.1.e003839.30","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1031920"},{"key":"2026090204550774000_13.1.e003839.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.010"},{"key":"2026090204550774000_13.1.e003839.32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.502815"},{"key":"2026090204550774000_13.1.e003839.33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12928-016-0417-x","article-title":"Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting","volume":"32","author":"Ueno","year":"2017","journal-title":"Cardiovasc Interv Ther"},{"key":"2026090204550774000_13.1.e003839.34","first-page":"E8","article-title":"Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study","volume":"95","author":"Kitano","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026090204550774000_13.1.e003839.35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"The Lancet"},{"key":"2026090204550774000_13.1.e003839.36","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1055\/a-1346-3300","article-title":"Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial","volume":"121","author":"Jeong","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026090204550774000_13.1.e003839.37","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-0266"},{"key":"2026090204550774000_13.1.e003839.38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12928-014-0277-1","article-title":"Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease","volume":"29","author":"Hiasa","year":"2014","journal-title":"Cardiovasc Interv Ther"},{"key":"2026090204550774000_13.1.e003839.39","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000460","article-title":"Bleeding events and maintenance dose of prasugrel: BLESS pilot study","volume":"3","author":"Carrabba","year":"2016","journal-title":"Open Heart"},{"key":"2026090204550774000_13.1.e003839.40","first-page":"905","article-title":"Efficacy and safty of different dose of ticagrelor in elderly women with acute myocardial infarction after primary PCI","volume":"24","author":"Wang","year":"2022","journal-title":"Chin J Geriatr Heart Brain Vessel Dis"},{"key":"2026090204550774000_13.1.e003839.41","first-page":"152","article-title":"Effect of low dose ticagrelor on coronary microcirculation, MHR, and NLR in peripheral blood of patients with stable coronary heart disease","volume":"11","author":"Lu","year":"2022","journal-title":"J Transl Med"},{"key":"2026090204550774000_13.1.e003839.42","first-page":"578","article-title":"Effect of Low-Dose Ticagrelor Combined with Aspirin on the Efficacy in Elderly Patients after Percutaneous Coronary Intervention","volume":"43","author":"Wang","year":"2021","journal-title":"Beijing Med J"},{"key":"2026090204550774000_13.1.e003839.43","first-page":"2465","article-title":"Efficacy of low-dose Ticagrelor in treatment of patients with unstable angina pectoris","volume":"43","author":"Ye","year":"2021","journal-title":"Zhejiang Med J"},{"key":"2026090204550774000_13.1.e003839.44","first-page":"133","article-title":"Impact of different doses of ticagrelor on adverse reactions and serum indexes levels in patients with myocardial infarction after percutaneous coronary intervention","volume":"23","author":"Cao","year":"2025","journal-title":"Chinese Journal of Cardiovascular Research"},{"key":"2026090204550774000_13.1.e003839.45","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/09537104.2018.1513479","article-title":"Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease","volume":"30","author":"He","year":"2019","journal-title":"Platelets"},{"key":"2026090204550774000_13.1.e003839.46","first-page":"255","article-title":"A pilot study on efficacy and safety profile of a low clopidogrel maintenance dose following drug eluting stent implantation","volume":"17","author":"Xu","year":"2009","journal-title":"Chinese Journal of Interventional Cardiology"},{"key":"2026090204550774000_13.1.e003839.47","first-page":"1257","article-title":"The Myocardial Protective Effect of Ticagrelor in Patients with ST-Segment Elevation Acute Coronary Syndrome Combined with Diabetes Mellitus","volume":"36","author":"Li","year":"2015","journal-title":"Guangdong Medical Journal"},{"key":"2026090204550774000_13.1.e003839.48","first-page":"50","article-title":"Comparative Study for Effectiveness and Safety in Acute Myocardial Infarction Patients Undergoing PCI betweenTicagrelor and Clopidogrel","volume":"25","author":"Hao","year":"2017","journal-title":"Journal of Practical Cardio-Cerebral-Pulmonary and Vascular Disease"},{"key":"2026090204550774000_13.1.e003839.49","first-page":"2480","article-title":"Safety and efficacy of low-dose ticagrelor in patients with unstable angina pectoris and non-revascularization","volume":"24","author":"Li","year":"2015","journal-title":"Chinese Journal of NewDrugs"},{"key":"2026090204550774000_13.1.e003839.50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jebm.12671","article-title":"Comparative Efficacy and Safety of Different Low-Dose Platelet Inhibitors in Patients With Coronary Heart Disease: A Bayesian Network Meta-Analysis","volume":"17","author":"Li","year":"2024","journal-title":"J Evid Based Med"},{"key":"2026090204550774000_13.1.e003839.51","doi-asserted-by":"crossref","unstructured":"Moffett DB , Mumtaz MM , Sullivan DW , et al . General considerations of dose-effect and dose-response relationships. In: Handbook on the toxicology of metals. 2022: 299\u2013317.","DOI":"10.1016\/B978-0-12-823292-7.00019-X"},{"key":"2026090204550774000_13.1.e003839.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.12.062"},{"key":"2026090204550774000_13.1.e003839.53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.thromres.2011.11.023","article-title":"Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention","volume":"129","author":"Yokoi","year":"2012","journal-title":"Thromb Res"},{"key":"2026090204550774000_13.1.e003839.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.010"},{"key":"2026090204550774000_13.1.e003839.55","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3109\/09537104.2015.1135890","article-title":"Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS","volume":"27","author":"Xue","year":"2016","journal-title":"Platelets"},{"key":"2026090204550774000_13.1.e003839.56","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-001999","article-title":"Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a \u201ctarget trial\u201d","volume":"9","author":"Pufulete","year":"2022","journal-title":"Open Heart"},{"key":"2026090204550774000_13.1.e003839.57","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw525"},{"key":"2026090204550774000_13.1.e003839.58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.21037\/cdt.2018.06.09","article-title":"Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare","volume":"8","author":"Esmonde","year":"2018","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026090204550774000_13.1.e003839.59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1055\/s-0043-1777794","article-title":"Ethnic Differences in Thrombotic Profiles of Acute Coronary Syndrome Patients and Relationship to Cardiovascular Outcomes: A Comparison of East Asian and White subjects","volume":"124","author":"Suh","year":"2024","journal-title":"Thromb Haemost"},{"key":"2026090204550774000_13.1.e003839.60","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvac040"},{"key":"2026090204550774000_13.1.e003839.61","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1128834","article-title":"Body mass index affecting ticagrelor monotherapy vs. ticagrelor with aspirin in patients with acute coronary syndrome: A pre-specified sub-analysis of the TICO randomized trial","volume":"10","author":"Kim","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026090204550774000_13.1.e003839.62","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-024-00699-1","article-title":"The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis","volume":"18","author":"Li","year":"2024","journal-title":"Hum Genomics"},{"key":"2026090204550774000_13.1.e003839.63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.5414\/CP202637","article-title":"Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study","volume":"55","author":"Eskandarian","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2026090204550774000_13.1.e003839.64","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12618","article-title":"Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)","volume":"5","author":"Khan","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2026090204550774000_13.1.e003839.65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39430.529549.BE"},{"key":"2026090204550774000_13.1.e003839.66","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.105"},{"key":"2026090204550774000_13.1.e003839.67","first-page":"1275","article-title":"Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis","volume":"84","author":"Maas","year":"2024","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026090204550774000_13.1.e003839.68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040167"},{"key":"2026090204550774000_13.1.e003839.69","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jacasi.2022.10.010","article-title":"De-Escalation Therapy After PCI in ACS Patients With Chronic Kidney Disease","volume":"3","author":"Natsuaki","year":"2023","journal-title":"JACC Asia"},{"key":"2026090204550774000_13.1.e003839.70","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation"},{"key":"2026090204550774000_13.1.e003839.71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.064264"},{"key":"2026090204550774000_13.1.e003839.72","first-page":"555","article-title":"Safety and efficacy of 6\u2010month versus 12\u2010month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer\u2010coated sirolimus\u2010eluting coronary stents: Insight from the I\u2010LOVE\u2010IT 2 trial","volume":"89","author":"Qi","year":"2017","journal-title":"Cathet Cardio Intervent"},{"key":"2026090204550774000_13.1.e003839.73","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005819","article-title":"Outcomes of \u22646-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression","volume":"95","author":"Villablanca","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:55:23Z","timestamp":1788350123000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/openhrt-2025-003839"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003839","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}